Table 4. Age-specific lung cancer death rates per 1 000 person-years at risk, by age group and amount smoked
|
Average number of cigarettes smoked daily
|
|
0
|
1-14
|
15-24
|
25+
|
Age group
|
Number
|
Rate
|
Number
|
rate
|
Number
|
rate
|
Number
|
rate
|
35-44
|
1
|
0,05
|
1
|
0,07
|
0
|
-
|
1
|
0,11
|
45-54
|
0
|
-
|
3
|
0,31
|
9
|
0,62
|
8
|
0,75
|
55-64
|
0
|
-
|
3
|
0,48
|
20
|
2,31
|
26
|
3,88
|
65-74
|
0
|
-
|
9
|
2,69
|
17
|
5,16
|
14
|
6,48
|
75+
|
2
|
1,11
|
6
|
2,68
|
8
|
7,27
|
8
|
16,33
|
Total all ages
(Standardized)
|
3
|
0,07
|
22
|
0,57
|
54
|
1,39
|
57
|
2,27
|
The relation between lung cancer mortality and cessation of smoking is shown in Table 5.
Table 5. Lung cancer deaths, rates in smokers, ex-smokers and non-smokers
Smoking habit
|
Number of lung cancer deaths
|
Rates per 1 000 person-years
|
Current smoker
|
124
|
1,28
|
Ex-smoker for:
|
|
|
<5 years
|
5
|
0,67
|
5-9 years
|
7
|
0,49
|
10-19 years
|
3
|
0,18
|
20+ years
|
2
|
0.19
|
Non-smoker
|
3
|
0,07
|
Questions re Cohort study
-
What proportion of male physicians answered the questionnaire? How might this affect comparability of smokers and non-smokers in the study?
-
From table 4, compute and interpret values of relative and attributable risk for the “total” group.
-
What do the data in table 5 imply for health education services?
Practical exercise
Clinical trials
The following are various scenarios illustrating clinical trials. Read the scenarios and answer the questions.
Scenario 1
A new anti-tuberculosis medication has been developed which has shown good in vitro activity and low toxicity in phase 2 (safety) trials. A randomised control clinical trial is now being planned.
Which of the following groups would you consider to be the most appropriate controls and why? What are the disadvantages of the groups you do not select?
|
|
No
|
Yes
|
1.
|
Patients who receive the current standard 2-drug therapy in your clinic
|
|
|
|
If no: disadvantages
|
|
|
2.
|
Patients who receive a placebo drug
|
|
|
|
If no: disadvantages
|
|
|
3.
|
Patients who receive only one of the two drugs in current use
|
|
|
|
If no: disadvantages
|
|
|
4.
|
Two groups, one on the current two drugs and one on placebo
|
|
|
|
If no: disadvantages
|
|
|
Scenario 2
In a trial of Haemophilus influenzae type b conjugate vaccine involving 60 000 infants, children born on odd dates during a twelve month period received the vaccine in a four dose schedule plus the routine infant immunisation schedule vaccines. Those born on even dates served as controls and received only the routine vaccine schedule.
What factors would have entered into the calculation of numbers of infants in the trial?
|
|
|
|
Was the method of allocation to vaccine and control groups satisfactory?
|
|
|
|
What alternative method might have been adopted?
|
|
|
|
How would you go about identifying cases of invasive Haemophilus disease?
|
|
|
|
What sources of bias might enter into case ascertainment?
|
|
|
|
Practical exercise
Advantages and Disadvantages of Different Study Designs
Complete this table by placing one or more “+” or “ –“ marks or short comments in the boxes to provide a quick comparison of the advantages and disadvantages of these different study designs.
|
Experi-mental study
|
Prospective cohort study
|
Retro-spective cohort study
|
Case-control study
|
Cross-sectional study
|
Descriptive (non-analytic) study
|
Can measure disease incidence
|
|
|
|
|
|
|
Can evaluate more than one outcome from the same risk factor
|
|
|
|
|
|
|
Can evaluate several different risk factors for the same disease
|
|
|
|
|
|
|
Follows the natural time sequence of exposure and disease
|
|
|
|
|
|
|
Useful for rare exposures or risk factors
|
|
|
|
|
|
|
Useful for rare diseases
|
|
|
|
|
|
|
Useful for diseases with long latency periods
|
|
|
|
|
|
|
Logistics? (eg. keeping track of study groups? Quality control in method?)
|
|
|
|
|
|
|
Number of subjects needed
|
|
|
|
|
|
|
Cost
|
|
|
|
|
|
|
Results available quickly
|
|
|
|
|
|
|
Uses existing data
|
|
|
|
|
|
|
Practical Exercise
Sampling a population
We propose to do a study of knowledge of tuberculosis in a group who are members of a scientific society. We have obtained a list of the members (see next page) from the register of members of the association and we will obtain a sample of the members to administer a questionnaire.
-
List the frequencies of the variables gender, language, region, TB and BACT.
-
Select the first 8 members in the list.
-
List the frequencies of the same variables in the table.
-
Select every 5th member in the list.
-
List the frequencies of the same variables in the table.
Variable
|
All members
|
First 8
|
Every 5th
|
|
|
|
|
Gender
|
|
|
|
Men
|
|
|
|
Women
|
|
|
|
Don’t know
|
|
|
|
Language
|
|
|
|
French
|
|
|
|
English
|
|
|
|
Spanish
|
|
|
|
Don’t know
|
|
|
|
TB
|
|
|
|
Yes
|
|
|
|
No
|
|
|
|
Don’t know
|
|
|
|
Bact
|
|
|
|
Yes
|
|
|
|
No
|
|
|
|
Don’t know
|
|
|
|
-
Are the three groups the same?
-
Which of the samples is closest to the whole group?
-
Why?
-
What conclusion would you draw about the geographic focus of the society from the first eight cases?
-
Why is this conclusion misleading?
-
What will be the effect of those cases where the value is not known?
List of members of a scientific society
NUMBER
|
GENDER
|
LANGUAGE
|
REGION
|
TB
|
BACT
|
|
|
|
|
|
|
1
|
MAN
|
SPANISH
|
AML
|
NO
|
NO
|
2
|
MAN
|
ENGLISH
|
AMN
|
YES
|
NO
|
3
|
MAN
|
ENGLISH
|
MIE
|
NO
|
NO
|
4
|
MAN
|
ENGLISH
|
MIE
|
NO
|
NO
|
5
|
MAN
|
ENGLISH
|
|
NO
|
NO
|
6
|
|
FRENCH
|
AFR
|
YES
|
YES
|
7
|
MAN
|
ENGLISH
|
ASI
|
YES
|
YES
|
8
|
MAN
|
ENGLISH
|
ASI
|
NO
|
YES
|
9
|
|
ENGLISH
|
AFR
|
NO
|
NO
|
10
|
MAN
|
ENGLISH
|
AFR
|
NO
|
NO
|
11
|
MAN
|
ENGLISH
|
AMN
|
NO
|
NO
|
12
|
MAN
|
FRENCH
|
AFR
|
YES
|
YES
|
13
|
MAN
|
ENGLISH
|
AFR
|
NO
|
NO
|
14
|
|
ENGLISH
|
MIE
|
NO
|
NO
|
15
|
MAN
|
ENGLISH
|
|
NO
|
NO
|
16
|
MAN
|
ENGLISH
|
AFR
|
NO
|
NO
|
17
|
WOMAN
|
SPANISH
|
AFR
|
YES
|
NO
|
18
|
WOMAN
|
SPANISH
|
AML
|
NO
|
NO
|
19
|
MAN
|
ENGLISH
|
MIE
|
YES
|
YES
|
20
|
MAN
|
SPANISH
|
AML
|
|
NO
|
21
|
|
SPANISH
|
AML
|
NO
|
NO
|
22
|
MAN
|
|
AFR
|
YES
|
NO
|
23
|
MAN
|
|
AMN
|
YES
|
YES
|
24
|
WOMAN
|
ENGLISH
|
AMN
|
YES
|
NO
|
25
|
MAN
|
ENGLISH
|
AFR
|
NO
|
NO
|
26
|
MAN
|
ENGLISH
|
AFR
|
NO
|
|
27
|
MAN
|
ENGLISH
|
AFR
|
NO
|
NO
|
28
|
|
ENGLISH
|
AMN
|
YES
|
NO
|
29
|
MAN
|
ENGLISH
|
ASI
|
NO
|
NO
|
30
|
|
ENGLISH
|
ASI
|
YES
|
YES
|
31
|
|
FRENCH
|
AFR
|
NO
|
NO
|
32
|
MAN
|
ENGLISH
|
AMN
|
YES
|
NO
|
33
|
WOMAN
|
FRENCH
|
AFR
|
NO
|
NO
|
34
|
MAN
|
ENGLISH
|
AFR
|
NO
|
NO
|
35
|
WOMAN
|
ENGLISH
|
EUR
|
NO
|
NO
|
36
|
MAN
|
ENGLISH
|
AMN
|
YES
|
YES
|
37
|
MAN
|
ENGLISH
|
EUR
|
NO
|
NO
|
38
|
MAN
|
ENGLISH
|
AFR
|
NO
|
NO
|
39
|
MAN
|
ENGLISH
|
ASI
|
NO
|
NO
|
40
|
MAN
|
ENGLISH
|
AFR
|
YES
|
NO
|
41
|
MAN
|
FRENCH
|
AFR
|
NO
|
NO
|
42
|
MAN
|
FRENCH
|
EUR
|
YES
|
YES
|
|
|
|
|
|
|
5>
Dostları ilə paylaş: |